

Startups
1-10 Employees
Velyon Health SystemsVELYON Health Systems is a pre-seed digital health venture developing VARAXIS, an early-stage multimodal wearable platform for longitudinal cardiovascular physiological monitoring. VARAXIS combines synchronized physiological signals to support the assessment of cardiovascular trends over time, with an initial research focus on patients undergoing potentially cardiotoxic cancer therapy. The project is currently focused on prototype development, signal-quality assessment and preparation for clinical validation.
Address
Calle Ator 2232, 45500 Guadalajara, Mexico
Details
Customer Problem
Cardiovascular deterioration can develop gradually and remain difficult to detect between conventional clinical assessments. Current monitoring often relies on intermittent measurements, specialized equipment, or hospital-based evaluations, leaving limited visibility into longitudinal physiological changes. This is particularly relevant in high-risk populations, such as patients receiving potentially cardiotoxic cancer therapies, where earlier recognition of meaningful cardiovascular trends could support more timely clinical assessment.Business Model
VELYON is developing a B2B business model centered on institutional deployment and strategic partnerships. The initial pathway focuses on research collaborations, clinical validation, and pilot programs with hospitals, research institutions, MedTech companies, and clinical-trial partners. Subject to successful validation and regulatory development, potential commercialization models include institutional licensing, recurring software and analytics services, device-based revenue, and technology licensing or OEM partnerships.Technology Description
VARAXIS is an early-stage multimodal wearable platform designed for non-invasive longitudinal cardiovascular monitoring. The platform is being developed to acquire and synchronize complementary physiological signals, including seismocardiography (SCG), photoplethysmography (PPG), and potentially bioimpedance (BioZ), with signal-quality assessment and artifact management. The objective is to characterize cardiovascular trends over time and generate clinically interpretable information while explicitly accounting for signal quality and uncertainty. The technology is currently in prototype development and requires clinical validation.Market Description
VELYON is initially targeting the digital health and cardiovascular monitoring market, with a focused entry strategy in cardio-oncology and clinical research. Initial customers and partners include hospitals, oncology and cardiology centers, academic research institutions, clinical-trial organizations, pharmaceutical companies, and MedTech companies seeking longitudinal physiological data outside conventional episodic assessments. Expansion into broader cardiovascular monitoring applications would depend on clinical validation and regulatory evidence.USP
VARAXIS is designed around multimodal, synchronized physiological sensing rather than reliance on a single surrogate signal. Its proposed differentiation is the integration of complementary cardiovascular signals with explicit signal-quality and confidence assessment to support longitudinal trend monitoring under real-world conditions. The initial focus on cardio-oncology provides a clinically defined validation pathway while maintaining the potential for broader cardiovascular applications if supported by evidence.Finance Data
| Date | Investors | Amount | Stage |
Financial Overview
No revenue recorded yet
Further information
SDGs (Sustainable Development Goals)
